Biotinidase Deficiency Genetic Test: BTD Gene Mutations and Results

A biotinidase deficiency genetic test analyzes the BTD gene for variants that impair recycling of biotin, a vitamin needed by several metabolic enzymes. Testing is commonly used after a low newborn-screening enzyme result, to confirm profound or partial deficiency, to investigate compatible neurologic or skin symptoms, and to identify relatives or reproductive carriers. DNA results are important, but biotinidase deficiency is unusual because a direct enzyme-activity measurement remains central to diagnosis. A child with a positive newborn screen generally needs prompt serum or plasma biotinidase testing and metabolic follow-up rather than waiting for sequencing alone. Profound deficiency means very low enzyme activity and can cause seizures, developmental problems, hearing or vision loss, rash, hair loss, breathing difficulty, and metabolic illness if untreated. Partial deficiency carries lower risk but may become clinically relevant during illness or stress. Lifelong oral free biotin is highly effective, especially when started before symptoms, so rapid and accurate interpretation matters.

• BTD variants cause an autosomal recessive disorder of biotin recycling.
• Serum or plasma enzyme activity helps distinguish profound, partial, carrier-range, and normal results.
• Genetic testing confirms the cause, resolves complex enzyme patterns, and supports family testing.
• Two pathogenic BTD variants are usually required for biotinidase deficiency.
• Common variants can have different effects depending on whether they occur alone, in cis, or in trans.
• Treatment should be directed by a metabolic specialist and should not be delayed in a newborn with strongly abnormal confirmatory findings.

Table of Contents

• What Biotinidase Does
• Who Needs BTD Testing
• Enzyme Testing After Newborn Screening
• How BTD Genetic Testing Works
• Interpreting BTD Variants
• Matching Genotype With Enzyme Activity
• Inheritance, Carrier, and Pregnancy Risk
• Treatment, Follow-Up, and Unresolved Results

What Biotinidase Does

Biotin, also called vitamin B7, acts as a cofactor for carboxylase enzymes involved in processing fats, amino acids, and carbohydrates. Much of the body’s biotin becomes attached to proteins. Biotinidase releases and recycles that bound biotin so it can be reused. BTD provides the instructions for the biotinidase enzyme.

When both BTD copies have disease-causing variants, enzyme activity may fall enough to create functional biotin deficiency despite an ordinary diet. Several biotin-dependent carboxylases then lose activity. This is why the disorder was historically described as late-onset or juvenile multiple carboxylase deficiency.

Profound biotinidase deficiency is generally defined as less than 10% of mean normal serum enzyme activity. Partial deficiency is generally 10% to 30%. These percentages are based on the laboratory’s validated reference range and assay conditions. A person with profound deficiency has the greatest risk of symptoms without treatment. Partial deficiency is usually milder, and symptoms may appear mainly during infection, prolonged fasting, or other physiologic stress.

Untreated manifestations vary. Infants or children may develop seizures, low muscle tone, developmental delay, balance problems, hearing loss, optic atrophy, vision changes, skin rash, hair loss, conjunctivitis, breathing problems, or metabolic acidosis. Some individuals present later with weakness, spasticity, vision loss, or hearing loss. The symptoms can resemble other neurologic, immune, nutritional, or metabolic disorders.

The condition is exceptionally important in newborn screening because presymptomatic treatment can prevent most manifestations. Oral pharmacologic biotin bypasses the recycling defect by providing enough free vitamin for the dependent enzymes. Treatment can improve many active symptoms, but established hearing loss, optic atrophy, or developmental injury may not fully reverse. Prevention is therefore better than rescue.

Biotinidase deficiency is distinct from holocarboxylase synthetase deficiency, which affects attachment of biotin to carboxylases and often presents earlier. Both can produce multiple carboxylase deficiency, but they involve different genes, enzyme tests, and management details. A low biotinidase enzyme result points toward BTD-related disease; an abnormal organic-acid pattern with normal biotinidase may prompt other testing.

Who Needs BTD Testing

The most common indication is an out-of-range newborn screen. Most programs measure biotinidase activity in a dried blood spot. Screening identifies babies who may be affected, but it is not diagnostic. A low screen requires rapid contact with the family, clinical assessment, confirmatory enzyme testing, and consultation with a metabolic specialist.

Diagnostic evaluation is also appropriate in an older child or adult with unexplained seizures, developmental regression, ataxia, spasticity, hearing or vision loss, recurrent rash, alopecia, metabolic acidosis, or a combination of neurologic and skin findings. Late presentation can occur when newborn screening was unavailable, was performed before the condition was added to a program, or produced a false-negative result.

BTD genetic testing may be ordered when:

• Serum or plasma biotinidase activity is in the profound or partial range.
• The enzyme result is borderline or conflicts with the clinical picture.
• A newborn screen is repeatedly low.
• A sibling or other relative has confirmed biotinidase deficiency.
• A reproductive carrier screen identifies a BTD variant.
• Prenatal or preimplantation testing is being planned.
• The person has taken high-dose biotin before biochemical evaluation and the diagnostic pathway needs clarification.

Testing can identify an affected person who has two pathogenic variants, an unaffected carrier with one, or an at-risk relative who did not inherit the familial variants. It may also reveal a complex allele, meaning two changes on the same BTD copy, that would be difficult to interpret from a short carrier-screen summary.

The clinical question should be clear on the laboratory order. Newborn confirmation, symptomatic diagnosis, and reproductive carrier screening are not identical tasks. A carrier panel may report selected pathogenic variants but may not include the enzyme assay. Conversely, an enzyme test establishes functional deficiency but does not identify the familial DNA changes needed for targeted testing.

Biotin supplements can interfere with many unrelated laboratory immunoassays, including some thyroid, hormone, and cardiac tests, but they do not correct the inherited DNA result. Patients should tell all clinicians and laboratories about prescribed biotin. They should not stop metabolic treatment without guidance merely to prepare for another blood test; the ordering team can coordinate timing or use an unaffected assay.

Enzyme Testing After Newborn Screening

A newborn screen measures risk at the population level. Confirmatory serum or plasma testing measures biotinidase activity under controlled conditions and is the key next step. The metabolic team interprets the value against the laboratory’s normal mean, not against a universal raw number.

The general activity categories are:

Enzyme activity	Common interpretation	Usual response
Less than 10% of mean normal	Profound biotinidase deficiency range	Urgent metabolic management, BTD testing, and treatment
10% to 30%	Partial deficiency range	Genetic confirmation and specialist-directed treatment
Approximately carrier/intermediate range	Possible heterozygous carrier, technical effect, or mild allele	Repeat/clarify testing and correlate with genotype
Normal range	Deficiency less likely	Review screen quality and alternative diagnoses if concern persists

These categories should not be applied mechanically. Specimen handling, temperature, transport delay, prematurity, illness, jaundice, liver dysfunction, and laboratory method can influence activity. Dried blood spots are particularly vulnerable to heat and humidity. A poorly preserved sample may yield a falsely low screen.

Confirmatory testing should use an appropriate fresh specimen and established assay. If the value is unexpectedly low in a well infant, the laboratory may repeat it before assigning a lifelong diagnosis. If it is profoundly low, treatment and specialist consultation should not be postponed while several sequential tests are completed.

The enzyme level can also help assess whether two BTD variants explain the phenotype. Two severe loss-of-function variants should generally match profound deficiency. A common mild variant paired with a severe variant often matches partial deficiency. If sequencing reports two apparently severe variants but enzyme activity is normal, sample identity, phase, classification, and assay results need review.

Carriers often have activity lower than the population mean but above the deficiency range. Enzyme activity alone is not always the best carrier test because distributions overlap. Once a familial variant is known, targeted DNA testing gives a clearer answer for relatives and reproductive partners.

Premature infants can pose special challenges because enzyme activity and sample quality may differ. Newborn screening programs may request a repeat dried blood spot, but a repeat screen is not a substitute for confirmatory serum testing when the first result is markedly abnormal. The local newborn-screening program and metabolic specialist should direct the sequence.

A symptomatic person may have abnormal urine organic acids, lactate, or other metabolic markers, but these can be normal between episodes. A normal metabolic profile does not exclude biotinidase deficiency if enzyme activity is low. The disorder should be evaluated directly rather than ruled out through nonspecific markers.

How BTD Genetic Testing Works

BTD testing usually analyzes DNA from blood, saliva, or a cheek swab. No fasting is required. Most clinical laboratories sequence the coding exons and nearby splice regions. Many also perform deletion and duplication analysis, although large copy-number changes are less common than small sequence variants.

Sequence analysis detects missense, nonsense, splice-site, and small insertion or deletion variants. A nonsense or frameshift change may prevent production of functional enzyme. A missense variant changes one amino acid and can have effects ranging from severe to minimal. Functional data and enzyme activity are especially helpful for missense interpretation.

Deletion/duplication analysis searches for missing or extra sections of BTD. A negative sequencing result does not exclude a copy-number variant unless this analysis was included. Broad exome or genome testing can identify BTD variants, but the report should still be paired with a direct enzyme assay before diagnosing deficiency.

Targeted testing is appropriate when the exact familial variant or variants are known. It is faster and simplifies interpretation, but it answers only whether the person inherited those changes. A reproductive partner of a carrier generally needs comprehensive BTD analysis rather than testing solely for the carrier’s exact variant, because partners can carry different pathogenic changes.

The report should provide standardized DNA and protein notation, the reference transcript, classification, zygosity, and method. In a person with two variants, it may state whether they are known or suspected to be in trans. Parental testing often establishes phase: one variant inherited from each parent supports an affected genotype, while two variants inherited together from one parent are in cis on the same allele.

Some laboratories report only pathogenic and likely pathogenic variants for carrier screening. Diagnostic testing may also report a variant of uncertain significance. A VUS is not proof of disease. It may become more or less concerning when considered with enzyme activity, the second BTD variant, family segregation, population frequency, and laboratory studies.

Turnaround commonly ranges from one to several weeks. This is slower than the clinical response needed for a strongly positive newborn confirmation. Genetic testing should run alongside, not ahead of, the immediate metabolic plan.

Interpreting BTD Variants

A BTD result is best read at three levels: how many variants were found, how they are classified, and how much enzyme activity remains. The same named variant can have different consequences depending on the variant on the other BTD copy.

Two pathogenic or likely pathogenic variants in trans. This supports biotinidase deficiency. The enzyme result usually determines whether the person is in the profound or partial range. Genotype can reinforce the classification but should not override a reliable biochemical result.

One pathogenic variant. This most often indicates carrier status. Carriers do not develop classic biotinidase deficiency and generally do not need pharmacologic biotin for the condition. If enzyme activity is in the deficiency range, the laboratory should search for a second variant, a deletion, a complex allele, or another explanation.

No pathogenic variant detected. This lowers the likelihood of BTD-related disease but does not erase a clearly abnormal enzyme result. The assay may not detect every regulatory or structural change. Repeat biochemical testing, deletion analysis, expanded sequencing, or consultation with a specialist laboratory may be needed.

A VUS. A VUS cannot establish an affected diagnosis or carrier status on its own. Strongly reduced enzyme activity can provide evidence that the overall genotype is clinically important, but the laboratory still must evaluate whether the VUS accounts for the deficit. General principles are described in a genetic variant interpretation guide.

One commonly encountered BTD change is p.Asp444His, also written D444H. By itself, it reduces enzyme activity but usually does not cause profound or partial deficiency in a person with a normal variant on the other copy. When D444H is in trans with a profound-deficiency variant, the combination commonly produces partial deficiency. When D444H occurs in cis with another pathogenic change on the same allele, the combined allele can have a more severe effect.

This cis/trans distinction is critical. A short report that lists two variants without phase can be misleading. The common complex allele containing p.Ala171Thr and p.Asp444His on the same chromosome is associated with severe loss of activity from that allele. Parental testing or laboratory haplotype knowledge can determine whether the changes travel together.

Variant classification should be based on more than how often a change appears online. Evidence includes enzyme measurements, segregation, functional studies, population frequency, predicted protein effect, and observations in affected people. Direct-to-consumer raw data may miscall rare variants and should be confirmed in a clinical laboratory.

Matching Genotype With Enzyme Activity

Concordance between genetics and enzyme function gives the strongest diagnosis. A child with less than 10% activity and two severe BTD variants has a clear profound-deficiency result. A child with 10% to 30% activity and a severe variant paired with D444H has a pattern consistent with partial deficiency. Discordant cases need investigation rather than forced categorization.

Possible reasons for discordance include:

• The enzyme sample was damaged during transport or stored incorrectly.
• The person was premature, acutely ill, or had liver dysfunction.
• The DNA assay missed a second variant or copy-number change.
• Two listed variants are in cis rather than in trans.
• A VUS was overclassified or a pathogenic variant was misinterpreted.
• The samples came from different people or were mislabeled.
• The laboratory used a reference range not appropriate to the specimen or method.

Repeating enzyme activity at a laboratory experienced with biotinidase testing is often useful. Testing both parents can establish phase and show whether each carries one variant. In an affected child, parental results also support recurrence counseling.

Treatment can begin before every discrepancy is resolved if the clinical and biochemical evidence indicates deficiency. Biotin is generally well tolerated, while untreated profound deficiency can cause irreversible injury. The metabolic specialist can later adjust the diagnosis and dose as confirmatory information becomes available.

Genotype does not reliably predict which untreated symptom would appear first or whether hearing and vision injury would occur. It is more dependable for explaining the enzyme range than for forecasting a detailed natural history. Early treatment changes that natural history dramatically.

A normal enzyme test in a person with two reported pathogenic variants deserves expert review. Rarely, a report may refer to variants associated with another proposed phenotype or use outdated classification. ClinGen currently supports a definitive BTD–biotinidase deficiency relationship, but not every clinical claim involving BTD has equal evidence.

Inheritance, Carrier, and Pregnancy Risk

Biotinidase deficiency is autosomal recessive. An affected person usually has one clinically significant BTD variant on each gene copy. The parents are typically carriers with one variant each.

When both reproductive partners carry pathogenic BTD variants, each pregnancy has:

• A 25% chance of inheriting both variants and being affected.
• A 50% chance of inheriting one variant and being an unaffected carrier.
• A 25% chance of inheriting neither familial variant.

The expected enzyme category in an affected child depends on the specific pair. Two profound-deficiency alleles are likely to produce profound deficiency. A profound allele paired with a partial allele may produce partial deficiency. Counseling should therefore address both the chance of inheriting two variants and the likely functional result.

If only one partner is a known carrier, the other partner can have comprehensive BTD testing. A negative result reduces but does not eliminate reproductive risk because no assay detects every possible variant. The couple’s residual risk depends on the partner’s background carrier probability and test sensitivity.

Full siblings of an affected person who are unaffected have a two-thirds chance of being carriers after excluding the affected outcome. Siblings should not be classified from enzyme activity alone when familial DNA testing is available. Adult relatives can use the exact familial variants for targeted testing.

An affected person will pass one pathogenic BTD variant to every biological child. If the reproductive partner is not a carrier, the children are expected to be carriers but not affected. If the partner is a carrier, each pregnancy commonly has a 50% chance of being affected and a 50% chance of being a carrier.

Prenatal diagnosis can test fetal DNA from chorionic villus sampling or amniocentesis for the known parental variants. IVF with PGT-M can test embryos before transfer. Because the condition is highly treatable after birth, families vary in whether they pursue prenatal diagnosis. Genetic counseling should provide neutral information about prognosis with early treatment, residual uncertainty, procedure considerations, and alternatives.

Newborn screening availability should be confirmed rather than assumed. Programs differ by country and region. Even where screening is routine, a known at-risk pregnancy should be documented so confirmatory testing and treatment are not delayed by administrative errors or a borderline screen.

Treatment, Follow-Up, and Unresolved Results

Profound biotinidase deficiency is treated with lifelong oral free biotin. Partial deficiency is also commonly treated, particularly because physiologic stress may expose vulnerability and biotin has a favorable safety profile. The metabolic specialist determines the dose and formulation. Multivitamins or food sources do not reliably provide the pharmacologic amount used for treatment.

Adherence matters. The inherited enzyme defect does not disappear when symptoms are absent. Stopping biotin can allow metabolic and neurologic problems to develop. Families should arrange uninterrupted access during travel, hospitalization, vomiting illness, or changes in insurance or pharmacy.

A presymptomatically treated infant generally has an excellent outlook. Follow-up may include development, hearing, vision, skin, neurologic examination, and review of treatment adherence. A person diagnosed after symptoms begin may need audiology, ophthalmology, neurology, developmental therapies, and rehabilitation in addition to metabolic care.

For an unresolved newborn result, the immediate checklist is practical:

1. Confirm that the family was reached and the infant was clinically assessed.
2. Obtain a fresh serum or plasma enzyme-activity test.
3. Consult a metabolic specialist.
4. Start biotin when confirmatory findings or clinical concern justify it.
5. Perform BTD sequencing with deletion/duplication analysis.
6. Compare genotype, phase, and enzyme activity before assigning profound or partial status.

A negative BTD test should not overrule repeated profound enzyme deficiency. Conversely, a carrier result should not lead to lifelong treatment when enzyme activity is normal. The two test types answer different questions and should be reconciled.

Seek urgent care for a baby with poor feeding, lethargy, breathing difficulty, unusual movements, persistent vomiting, or low muscle tone, especially after an abnormal newborn screen. Older untreated individuals with seizures, sudden vision changes, weakness, or altered consciousness also need prompt evaluation. Do not wait for a scheduled genetics appointment during an acute illness.

Finally, keep copies of the newborn screen, confirmatory enzyme values, molecular report, prescribed dose, and specialist contact information. These records prevent confusion when care moves between hospitals and allow relatives to receive accurate targeted testing.

References

• Biotinidase Deficiency 2023 (GeneReviews)
• Newborn Screening ACT Sheets and Algorithms: Biotinidase Deficiency 2022 (ACMG Clinical Action Resource)
• BTD and Biotinidase Deficiency Gene-Disease Validity 2023 (ClinGen Expert Curation)
• Evaluating reproductive carrier screening using biotinidase deficiency as a model 2025 (Research Article)
• Biotinidase deficiency: A treatable neurometabolic disorder 2024 (Review)
• Biotinidase Deficiency (BTD) Sequencing 2025 (Laboratory Test Fact Sheet)

Disclaimer

This article is educational and does not replace newborn-screening follow-up, metabolic evaluation, or genetic counseling. A low newborn screen requires prompt confirmatory enzyme testing and specialist guidance; do not delay urgent assessment or prescribed biotin while awaiting DNA results. Biotin dosing and any interruption of treatment should be directed by the treating metabolic team.